Pyrazole Compounds for Selective JAK Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for ligands that inhibit or modulate the activity of Janus kinases (JAKs) to address dysregulated JAK-mediated responses associated with various diseases, including cancers and immune-related conditions, as the JAK/STAT pathway plays a crucial role in cell growth, differentiation, and immune responses.
Innovation Solution
Development of pyrazole compounds that target JAKs, specifically Janus kinases, to modulate their activity and provide therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If JAK kinase inhibitors are developed to treat diseases, then therapeutic efficacy is improved, but potential side effects and toxicity may increase
Solution Approach 1:
The patent applies local quality by designing pyrazole compounds with specific substituent patterns at different positions of the molecular structure. Different R groups (R1-R12) are strategically placed to optimize binding to specific JAK isoforms while minimizing off-target effects. This localized structural modification allows selective inhibition of pathogenic JAK activity while preserving essential physiological functions, thereby improving therapeutic efficacy while reducing side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the pyrazole core structure, including substituent types, positions, and stereochemistry. By optimizing parameters such as hydrophobicity, molecular weight, and functional group composition, the compounds achieve enhanced potency and selectivity against JAK kinases. This parameter optimization allows fine-tuning of the risk-benefit ratio to maximize therapeutic value while minimizing adverse effects.
2Adaptability or versatility
If broad-spectrum JAK inhibition is achieved, then coverage of multiple disease indications is improved, but selectivity and off-target effects deteriorate
Solution Approach 1:
The patent applies universality by designing pyrazole compounds that can inhibit multiple JAK isoforms (JAK1, JAK2, JAK3, TYK2) with a single molecular structure. The core pyrazole scaffold with specific substituent patterns enables broad-spectrum JAK inhibition, allowing one compound to treat various diseases driven by different JAK pathways, including cancers, autoimmune disorders, and inflammatory conditions.
Solution Approach 2:
The patent reconciles broad-spectrum inhibition with selectivity by applying local quality through precise substituent placement. Specific R groups at defined positions on the pyrazole ring provide isoform-selective interactions while the core structure maintains broad JAK coverage. This localized differentiation allows the compounds to achieve multi-indication efficacy while minimizing off-target effects on non-JAK proteins.
Data Source
AI summary
Provided herein are pyrazole compounds. In particular, provided herein are compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds provided herein are useful in the treatment of a variety of diseases and conditions including cardiovascular diseases, JAK-associated diseases, such as diseases characterized by abnormal growth, such as cancers, and inflammatory diseases, or eye diseases such as glaucoma. Also provided herein are compositions comprising pyrazole compounds.